Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2021-12, Vol.16 (12), p.1994-1998
Hauptverfasser:	Aredo, Jacqueline V., Hellyer, Jessica A., Neal, Joel W., Wakelee, Heather A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - adverse effects Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Consolidation Chemotherapy ErbB Receptors - genetics Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	1998
container_issue	12
container_start_page	1994
container_title	Journal of thoracic oncology
container_volume	16
creator	Aredo, Jacqueline V. Hellyer, Jessica A. Neal, Joel W. Wakelee, Heather A.
description
doi_str_mv	10.1016/j.jtho.2021.07.033
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2601483336</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1556086421023935</els_id><sourcerecordid>2601483336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-7ec8a2c6bb387f9349ca427c66a5fefa30b6f6de2323852023f57cd9093191613</originalsourceid><addsrcrecordid>eNp9kEtv1DAUhS0Eog_4AyyQl2ySXseJ40hsSuhjpKEgBsTSOPYN41ESF9upxL9vRjPtktW9i-8c6XyEvGOQM2DiYpfv0tbnBRQshzoHzl-QU1ZVImNcwsvjD1KUJ-Qsxh1AWUEpX5MTXkpoJPBT8rv1U_SDszo5P9HPc3jQwzzqjm62fh4svfOJfkJ6aUc3uZgwoKXJ028Lj1OK9JdLW7pJ-g_S1WpFr26uv2df5qSnRO827bp9Q171eoj49njPyc_rqx_tbbb-erNqL9eZKQFSVqORujCi67is-4aXjdFlURshdNVjrzl0ohcWC15wWS2TeV_VxjbQcNYwwfg5-XDovQ_-74wxqdFFg8OgJ_RzVIUAVkrOuVjQ4oCa4GMM2Kv74EYd_ikGam9W7dTerNqbVVCrxewSen_sn7sR7XPkSeUCfDwAuKx8cBhUNIsig9YFNElZ7_7X_wjdDohc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2601483336</pqid></control><display><type>article</type><title>Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Aredo, Jacqueline V. ; Hellyer, Jessica A. ; Neal, Joel W. ; Wakelee, Heather A.</creator><creatorcontrib>Aredo, Jacqueline V. ; Hellyer, Jessica A. ; Neal, Joel W. ; Wakelee, Heather A.</creatorcontrib><identifier>ISSN: 1556-0864</identifier><identifier>EISSN: 1556-1380</identifier><identifier>DOI: 10.1016/j.jtho.2021.07.033</identifier><identifier>PMID: 34809803</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antibodies, Monoclonal - adverse effects ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Consolidation Chemotherapy ; ErbB Receptors - genetics ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics</subject><ispartof>Journal of thoracic oncology, 2021-12, Vol.16 (12), p.1994-1998</ispartof><rights>2021 International Association for the Study of Lung Cancer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-7ec8a2c6bb387f9349ca427c66a5fefa30b6f6de2323852023f57cd9093191613</citedby><cites>FETCH-LOGICAL-c400t-7ec8a2c6bb387f9349ca427c66a5fefa30b6f6de2323852023f57cd9093191613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34809803$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aredo, Jacqueline V.</creatorcontrib><creatorcontrib>Hellyer, Jessica A.</creatorcontrib><creatorcontrib>Neal, Joel W.</creatorcontrib><creatorcontrib>Wakelee, Heather A.</creatorcontrib><title>Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC</title><title>Journal of thoracic oncology</title><addtitle>J Thorac Oncol</addtitle><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Consolidation Chemotherapy</subject><subject>ErbB Receptors - genetics</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><issn>1556-0864</issn><issn>1556-1380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtv1DAUhS0Eog_4AyyQl2ySXseJ40hsSuhjpKEgBsTSOPYN41ESF9upxL9vRjPtktW9i-8c6XyEvGOQM2DiYpfv0tbnBRQshzoHzl-QU1ZVImNcwsvjD1KUJ-Qsxh1AWUEpX5MTXkpoJPBT8rv1U_SDszo5P9HPc3jQwzzqjm62fh4svfOJfkJ6aUc3uZgwoKXJ028Lj1OK9JdLW7pJ-g_S1WpFr26uv2df5qSnRO827bp9Q171eoj49njPyc_rqx_tbbb-erNqL9eZKQFSVqORujCi67is-4aXjdFlURshdNVjrzl0ohcWC15wWS2TeV_VxjbQcNYwwfg5-XDovQ_-74wxqdFFg8OgJ_RzVIUAVkrOuVjQ4oCa4GMM2Kv74EYd_ikGam9W7dTerNqbVVCrxewSen_sn7sR7XPkSeUCfDwAuKx8cBhUNIsig9YFNElZ7_7X_wjdDohc</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Aredo, Jacqueline V.</creator><creator>Hellyer, Jessica A.</creator><creator>Neal, Joel W.</creator><creator>Wakelee, Heather A.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202112</creationdate><title>Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC</title><author>Aredo, Jacqueline V. ; Hellyer, Jessica A. ; Neal, Joel W. ; Wakelee, Heather A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-7ec8a2c6bb387f9349ca427c66a5fefa30b6f6de2323852023f57cd9093191613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Consolidation Chemotherapy</topic><topic>ErbB Receptors - genetics</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aredo, Jacqueline V.</creatorcontrib><creatorcontrib>Hellyer, Jessica A.</creatorcontrib><creatorcontrib>Neal, Joel W.</creatorcontrib><creatorcontrib>Wakelee, Heather A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thoracic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aredo, Jacqueline V.</au><au>Hellyer, Jessica A.</au><au>Neal, Joel W.</au><au>Wakelee, Heather A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC</atitle><jtitle>Journal of thoracic oncology</jtitle><addtitle>J Thorac Oncol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>16</volume><issue>12</issue><spage>1994</spage><epage>1998</epage><pages>1994-1998</pages><issn>1556-0864</issn><eissn>1556-1380</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34809803</pmid><doi>10.1016/j.jtho.2021.07.033</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 1556-0864
ispartof	Journal of thoracic oncology, 2021-12, Vol.16 (12), p.1994-1998
issn	1556-0864 1556-1380
language	eng
recordid	cdi_proquest_miscellaneous_2601483336
source	MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects	Antibodies, Monoclonal - adverse effects Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Consolidation Chemotherapy ErbB Receptors - genetics Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics
title	Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T18%3A15%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Consolidation%20Durvalumab%20Should%20Not%20Be%20Administered%20to%20Patients%20With%20Stage%20III%20EGFR-Mutant%20NSCLC&rft.jtitle=Journal%20of%20thoracic%20oncology&rft.au=Aredo,%20Jacqueline%20V.&rft.date=2021-12&rft.volume=16&rft.issue=12&rft.spage=1994&rft.epage=1998&rft.pages=1994-1998&rft.issn=1556-0864&rft.eissn=1556-1380&rft_id=info:doi/10.1016/j.jtho.2021.07.033&rft_dat=%3Cproquest_cross%3E2601483336%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2601483336&rft_id=info:pmid/34809803&rft_els_id=S1556086421023935&rfr_iscdi=true